AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14647955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 15 or 30 mg/70 kg i.v.)
Number of subjects: 0
Study 14647955 — intervention group
Group type: EXPERIMENTAL
Intervention: Active priming injection of cocaine (0, 15 or 30 mg/70 kg)
Number of subjects: 0
Study 14647955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12411657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1728
Study 12411657 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (background risk)
Number of subjects: 1728
Study 10190775 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 80% VO2max to fatigue (mean 37 min)
Number of subjects: 18
Study 10190775 — intervention group
Group type: COMPARATOR
Intervention: Exercise at 55% VO2max for 3 hours or to fatigue
Number of subjects: 18
Study 10190775 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after prolonged exercise at 55% VO2max
Number of subjects: 18
Study 7606530 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 240
Study 7606530 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal elderly subjects
Number of subjects: 240
Study 7606530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusitis patients
Number of subjects: 240
Study 7606530 — intervention group
Group type: COMPARATOR
Intervention: Normal elderly
Number of subjects: 240
Study 7606530 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's disease and sinusitis patients
Number of subjects: 240
Study 2405784 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 40
Study 2405784 — intervention group
Group type: COMPARATOR
Intervention: Control (no white noise)
Number of subjects: 40
Study 6892625 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein administered by intravenous drip infusion at 2 nanograms/kg/minute, starting 24 hours after surgery.
Number of subjects: 0
Study 6892625 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no drugs or manipulation (except nasogastric tube for aspiration and water/electrolyte replenishment).
Number of subjects: 0
Study 30844808 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI-27483-gemcitabine
Number of subjects: 42
Study 30844808 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 42
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 1011
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty and race
Number of subjects: 1011
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction effect of race and puberty
Number of subjects: 1011
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal influence on fitness
Number of subjects: 1011
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations between fitness and race/puberty
Number of subjects: 1011
Study 26942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Target group for fitness interventions
Number of subjects: 1011
Study 25630353 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1575
Study 25630353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine, Gabapentin, Oxcarbazepine, Topiramate, Valproate
Number of subjects: 1575
Study 25630353 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued seizures, adverse events, and failure of initial treatment
Number of subjects: 1575
Study 25630353 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month remission
Number of subjects: 1575
Study 25630353 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment withdrawal
Number of subjects: 1575
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexuality discussions during health maintenance visits
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations with explicit confidentiality discussions
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: African American adolescents
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer overall visit duration
Number of subjects: 253
Study 24378686 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian physicians
Number of subjects: 253
Study 23520669 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation plus topical application of honey
Number of subjects: 55
Study 23520669 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 55
Study 20175802 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg)
Number of subjects: 30
Study 20175802 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 30
Study 20175802 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg)
Number of subjects: 30
Study 20175802 — intervention group
Group type: COMPARATOR
Intervention: No ARB (Control)
Number of subjects: 30
Study 17589364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 32
Study 17589364 — intervention group
Group type: COMPARATOR
Intervention: Nonresurfaced patella
Number of subjects: 32
Study 17589364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 32
Study 15374773 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day of atorvastatin
Number of subjects: 8888
Study 15374773 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day of simvastatin (increased to 40 mg/day at week 24 if cholesterol levels remained high)
Number of subjects: 8888
Study 11195258 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective reuptake inhibitors (SRIs) reinstated at the same daily dose as in the acute phase for 24 weeks
Number of subjects: 81
Study 11229787 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specific drugs not mentioned)
Number of subjects: 0
Study 11229787 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed study design features
Number of subjects: 0
Study 9204594 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 28 days, amoxicillin 3 x 500 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Number of subjects: 60
Study 9204594 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 28 days, ACA (amoxicillin 500 mg plus clavulanic acid 125 mg) 3 x 625 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Number of subjects: 60
Study 8128836 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (intravenous, 2 hours)
Number of subjects: 27
Study 8128836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydroaminoacridine (THA, mean dose 104 ± 20 mg/day, 6 weeks)
Number of subjects: 27
Study 8128836 — intervention group
Group type: EXPERIMENTAL
Intervention: THA + lecithin (6 weeks)
Number of subjects: 27
Study 8128836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 27
Study 3602101 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet Ice (WI)
Number of subjects: 10
Study 3602101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Ice (DI)
Number of subjects: 10
Study 3602101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryogenic Packs (CGP)
Number of subjects: 10
Study 2202548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole (600 mg vaginal ovule)
Number of subjects: 153
Study 2202548 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (500 mg vaginal tablet)
Number of subjects: 153
Study 1093551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg/day
Number of subjects: 41
Study 1093551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 41
Study 1093551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (both dosages)
Number of subjects: 41
Study 30378456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 82
Study 30378456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 27814307 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Number of subjects: 40
Study 27814307 — intervention group
Group type: COMPARATOR
Intervention: Placebo shock wave therapy
Number of subjects: 40
Study 24971676 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity running training (TRA)
Number of subjects: 16
Study 24971676 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 16
Study 21928913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release (12.5 mg)
Number of subjects: 15
Study 19574798 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (Act‐D) 10 microg/kg per day for 5 days every 2 weeks
Number of subjects: 49
Study 19574798 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate-folinic acid (MTX‐FA) 1 mg/kg per day on days 1, 3, 5, and 7 with folinic acid 0.1 mg/kg per day on days 2, 4, 6, and 8 every 2 weeks
Number of subjects: 49
Study 17610766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy using PSSCogReHab for 10 weeks
Number of subjects: 12
Study 17610766 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (no intervention)
Number of subjects: 12
Study 17610766 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants (no intervention)
Number of subjects: 12
Study 15117561 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural honey (75 g in 250 mL of water)
Number of subjects: 40
Study 15117561 — intervention group
Group type: COMPARATOR
Intervention: Dextrose solution (75 g in 250 mL of water)
Number of subjects: 40
Study 15117561 — intervention group
Group type: COMPARATOR
Intervention: Artificial honey (35 g dextrose and 40 g fructose in 250 mL of water)
Number of subjects: 40
Study 15117561 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey solution (administered for 15 days)
Number of subjects: 40
Study 15117561 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (administered for 15 days)
Number of subjects: 40
Study 15117561 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (70 g)
Number of subjects: 40
Study 15117561 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (30 g)
Number of subjects: 40
Study 15117561 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (30 g)
Number of subjects: 40
Study 11961050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical ALA (1.328 g)
Number of subjects: 14
Study 11961050 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ALA (100 mg)
Number of subjects: 14
Study 11961050 — intervention group
Group type: COMPARATOR
Intervention: Oral ALA (100 mg)
Number of subjects: 14
Study 9792048 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy and surgery
Number of subjects: 0
Study 9792048 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 7891249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival chlorexidine gel
Number of subjects: 26
Study 7891249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival tetracycline paste
Number of subjects: 26
Study 7891249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 2105048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 92
Study 351906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 351906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31140432 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based instruction (WI), virtual reality (VR), and simulation exercise (SE) in three different instructional sequences (WI-VR-SE, WI-SE-VR, SE-WI-VR)
Number of subjects: 198
Study 31140432 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-WI-VR
Number of subjects: 198
Study 31140432 — intervention group
Group type: COMPARATOR
Intervention: WI-VR-SE and WI-SE-VR
Number of subjects: 198
Study 28027521 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe infection during NACT (defined as febrile neutropenia or any other grade III-IV infective adverse event)
Number of subjects: 1856
Study 28027521 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of the IRF7 gene signature (N=160)
Number of subjects: 1856
Study 28027521 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of the IRF7 gene signature
Number of subjects: 1856
Study 25880388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMF)
Number of subjects: 102
Study 25880388 — intervention group
Group type: COMPARATOR
Intervention: Standard health care (placebo)
Number of subjects: 102
Study 24696570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameera Pannaga Rasa at a dose of 30 mg twice a day for 4 weeks along with Nagavallidala (leaf of Piper betel Linn.)
Number of subjects: 52
Study 21358290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 12
Study 21358290 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 0 mg
Number of subjects: 12
Study 19073361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 40
Study 19073361 — intervention group
Group type: COMPARATOR
Intervention: Family physician usual care (control)
Number of subjects: 40
Study 17604744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern (<20% energy from fat, > or = 5 servings fruits/vegetables daily, and > or = 6 servings grains daily)
Number of subjects: 19541
Study 17604744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern maintenance
Number of subjects: 19541
Study 15078732 — intervention group
Group type: EXPERIMENTAL
Intervention: Firefighters who arrived before/during the WTC collapse
Number of subjects: 362
Study 15078732 — intervention group
Group type: EXPERIMENTAL
Intervention: Firefighters who arrived 1 to 2 days after the collapse
Number of subjects: 362
Study 15078732 — intervention group
Group type: EXPERIMENTAL
Intervention: Firefighters who arrived 3 to 7 days after the collapse
Number of subjects: 362
Study 15078732 — intervention group
Group type: COMPARATOR
Intervention: Unexposed firefighters
Number of subjects: 362
Study 11978282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 97
Study 11978282 — intervention group
Group type: COMPARATOR
Intervention: Maylard incision
Number of subjects: 97
Study 9786094 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 9786094 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaugmented repair using the Palmer technique
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with synthetic augmentation
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with biologic augmentation (patellar tendon)
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: New and complete ruptures of one of the menisci
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical bone changes in the femoral condyles
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging signals in the repaired ligament augmented with the patellar tendon
Number of subjects: 52
Study 8600742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaugmented and ligament augmentation device‐augmented repairs
Number of subjects: 52
Study 2806701 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0
Study 2806701 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 0
Study 2806701 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' agreement to participate in a subsequent study
Number of subjects: 0
Study 2806701 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' agreement for patient participation
Number of subjects: 0
Study 1234497 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 66,082 (200 mg)
Number of subjects: 6
Study 1234497 — intervention group
Group type: COMPARATOR
Intervention: Water (control treatment)
Number of subjects: 6
Study 31518599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-clip finger pulse oximeter
Number of subjects: 0
Study 31518599 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiogram (ECG)
Number of subjects: 0
Study 31518599 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 0
Study 31518599 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-clip oximeter
Number of subjects: 0
Study 31518599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-clip oximeter
Number of subjects: 0
Study 29793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Rest (SR) of 1 min between exercise sets (n=10)
Number of subjects: 20
Study 29793516 — intervention group
Group type: COMPARATOR
Intervention: Full Rest (FR) of 4 min between exercise sets (n=10)
Number of subjects: 20
Study 27621608 — intervention group
Group type: EXPERIMENTAL
Intervention: T+O 5/5 μg
Number of subjects: 413
Study 27621608 — intervention group
Group type: EXPERIMENTAL
Intervention: T+O 2.5/5 μg
Number of subjects: 413
Study 27621608 — intervention group
Group type: EXPERIMENTAL
Intervention: T+O 5/5 μg and T+O 2.5/5 μg
Number of subjects: 413
Study 24559009 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with physical exercise (MEDE)
Number of subjects: 36
Study 24559009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat and rich in complex carbohydrates diet with physical exercise (CHOE)
Number of subjects: 36
Study 24559009 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (MED)
Number of subjects: 36
Study 24559009 — intervention group
Group type: COMPARATOR
Intervention: Low fat and rich in complex carbohydrates diet (CHO)
Number of subjects: 36
Study 22708881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 57
Study 22708881 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition (start cognitive behaviour therapy after 6 months)
Number of subjects: 57
Study 21163776 — intervention group
Group type: EXPERIMENTAL
Intervention: e-therapy program (n = 78)
Number of subjects: 156
Study 21163776 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group (n = 78)
Number of subjects: 156
Study 18372693 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (treadmill under LBNP and flywheel)
Number of subjects: 24
Study 18372693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (daily protein supplement)
Number of subjects: 24
Study 18372693 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study 16425428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM) treatment
Number of subjects: 156
Study 16425428 — intervention group
Group type: COMPARATOR
Intervention: Genotype D, CD, and non-classified type
Number of subjects: 156
Study 16425428 — intervention group
Group type: COMPARATOR
Intervention: Non-classified types
Number of subjects: 156
Study 11756059 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fats (lipase-structured fat, chemically structured fat, physically mixed fat)
Number of subjects: 11
Study 11756059 — intervention group
Group type: COMPARATOR
Intervention: Conventional fat (rapeseed oil)
Number of subjects: 11
Study 11756059 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 test fats
Number of subjects: 11
Study 9526817 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5, 20, and 80 mg/day
Number of subjects: 2689
Study 9526817 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 2689
Study 9526817 — intervention group
Group type: EXPERIMENTAL
Intervention: All statins
Number of subjects: 2689
Study 9526817 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline triglyceride levels
Number of subjects: 2689
Study 9526817 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride/LDL cholesterol ratio
Number of subjects: 2689
Study 7857347 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod
Number of subjects: 120
Study 2777499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (dl-alpha-tocopherol IM, 175 mg/kg over four weeks)
Number of subjects: 29
Study 2777499 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented infants)
Number of subjects: 29
Study 1090103 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (Lioresal)
Number of subjects: 17
Study 1090103 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 17
Study 31943301 — intervention group
Group type: EXPERIMENTAL
Intervention: New complete dentures (CDs)
Number of subjects: 20
Study 31943301 — intervention group
Group type: COMPARATOR
Intervention: Old and unsatisfactory complete dentures (CDs)
Number of subjects: 20
Study 30657230 — intervention group
Group type: EXPERIMENTAL
Intervention: I Can Cope (ICC)
Number of subjects: 104
Study 30657230 — intervention group
Group type: COMPARATOR
Intervention: Open Airways for Schools (OAS)
Number of subjects: 104
Study 30657230 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 104
Study 29417786 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge assessment regarding vaccine preventable diseases
Number of subjects: 177
Study 26238111 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment (manual acupuncture plus electroacupuncture)
Number of subjects: 120
Study 26238111 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture control (sham acupuncture plus placebo acupuncture without electrical stimulation)
Number of subjects: 120
Study 26238111 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 120
Study 26238111 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 120
Study 24145706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and nitrous oxide
Number of subjects: 52